Original research
Endocrinology and Diabetology
Original research relevant to this speciality, newest first.
- Chronic immune-related toxicity affects nearly half of patients receiving adjuvant anti–PD-1 for melanoma
JAMA Network Open
Multicentre cohort, 303 patients. Chronic adverse events occurred in 48%, supporting continued monitoring after treatment ends. - Iatrogenic menopause before age 45 is associated with increased cardiovascular and overall mortality
JAMA Network Open
Meta-analysis, 36 studies and approximately 2.6 million women. Cardiovascular morbidity was elevated; mortality excess was concentrated in earlier menopause. - Survodutide reduces weight and HbA1c in adults with obesity and type 2 diabetes
NEJM
SYNCHRONIZE-2 phase 3 trial, 752 participants. Weight change at 76 weeks reached −9.8% versus −3.9% with placebo; gastrointestinal adverse events were common. - Low-dose interleukin-2 fails to preserve beta-cell function in newly diagnosed type 1 diabetes
The Lancet Diabetes & Endocrinology
DIABIL-2 randomized trial, 141 participants. Regulatory T cells increased, but the primary C-peptide outcome did not improve. - Orforglipron meets cardiovascular noninferiority versus insulin glargine in high-risk type 2 diabetes
The Lancet
ACHIEVE-4 phase 3 trial, 2,749 patients. Cardiovascular events: 4.2% versus 5.0%, HR 0.84. This establishes noninferiority, not cardiovascular superiority. - Retatrutide produces substantial weight loss in adults with obesity without diabetes
NEJM
TRIUMPH-1 phase 3 trial, 2,339 participants. Treatment-regimen estimate at 80 weeks: up to 25.0% weight loss versus 3.9% with placebo. - Retatrutide produces substantial weight loss in adults with obesity and type 2 diabetes
The Lancet
Phase 3, 1,152 participants. At 80 weeks, weight fell 18.8% with 12 mg versus 5.1% with placebo, using the primary treatment-regimen estimand. Gastrointestinal adverse effects were more frequent. - Oral safiglipron improves HbA1c and weight in early type 2 diabetes
Nature Medicine
Phase 3, 284 adults. Placebo-adjusted HbA1c reduction up to 1.45 percentage points at 32 weeks; no cardiovascular-outcome evidence. - Petrelintide reduces weight in a phase 2 obesity trial
The Lancet Diabetes & Endocrinology
Phase 2. Weight loss up to 9.8% versus 1.7% at the 28-week primary endpoint. No direct comparison with GLP-1 drugs. - Short oral corticosteroid courses were associated with serious adverse events in adults with type 2 diabetes.
JAMA Network Open
Self-controlled study of 36,048 patients. Increased gastrointestinal bleeding, pneumonia and heart failure during days 6–30 after initiation. - Setmelanotide reduced BMI and hunger in acquired hypothalamic obesity, with more serious adverse events.
NEJM